Brooklyn, NY – According to filings with the U.S. Securities and Exchange Commission, Accutar Biotechnology is raising $28,452,239.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jie Fan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Accutar Biotechnology

AccutarBio employs artificial intelligence to revolutionize drug discovery. With capabilities in side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction, Accutar’s platform beats the industry standard in computation-aided drug design. The company’s hybrid based approach, which uses computational drug design followed by wet lab validation, greatly reduces the time and cost necessary for traditional drug discovery efforts. Accutar is committed to building strong partnerships, and collaborates across academia and the pharmaceutical industry to solve interdisciplinary problems. The company was founded in 2015 and has locations in both Shanghai, China and New York, NY.

To learn more about Accutar Biotechnology, visit http://www.accutarbio.com/

Contact:
Jie Fan, Chief Executive Officer
646-462-5083
jiefan@accutarbio.com
https://www.linkedin.com/in/jie-fan-b57434aa/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved